SR 103
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2026-05-05
Current Status:
In Progress
(2026-05-04: Read. Adopted. (Ayes 40. Noes 0. Page 4134.))
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
WHEREAS, Serious mental illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise; and
WHEREAS, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities; and
WHEREAS, People at higher risk of TD include those 55 years of age or older, Black individuals, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure; and
WHEREAS, Approximately 60 percent of the estimated 800,000 adults in the United States living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention; and
WHEREAS, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment, and individuals treated with antipsychotics or experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings, and determine appropriate treatment together; and
WHEREAS, Treatments approved by the United States Food and Drug Administration for TD can provide options for symptom management and improved quality of life for many individuals living with TD; and
WHEREAS, California can encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings; now, therefore, be it
Resolved by the Senate of the State of California, That the Senate proclaims the first full week in May 2026 as Tardive Dyskinesia Awareness Week (TDAW), and, in recognition and support of TDAW, underscores the importance of early detection and intervention to improve outcomes for people living with mental health conditions and prescribed antipsychotics and supports efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
WHEREAS, Serious mental illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise; and
WHEREAS, While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities; and
WHEREAS, People at higher risk of TD include those 55 years of age or older, Black individuals, women, individuals with mood or substance use disorders, intellectual disabilities, or central nervous system injuries, and those with high cumulative antipsychotic exposure; and
WHEREAS, Approximately 60 percent of the estimated 800,000 adults in the United States living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention; and
WHEREAS, The American Psychiatric Association recommends routine TD screening in their clinical guidelines for antipsychotic treatment, and individuals treated with antipsychotics or experiencing abnormal movements should consult their health care providers to assess TD risk, receive TD screenings, and determine appropriate treatment together; and
WHEREAS, Treatments approved by the United States Food and Drug Administration for TD can provide options for symptom management and improved quality of life for many individuals living with TD; and
WHEREAS, California can encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings; now, therefore, be it
Resolved by the Senate of the State of California, That the Senate proclaims the first full week in May 2026 as Tardive Dyskinesia Awareness Week (TDAW), and, in recognition and support of TDAW, underscores the importance of early detection and intervention to improve outcomes for people living with mental health conditions and prescribed antipsychotics and supports efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| May 4, 2026 | Read. Adopted. (Ayes 40. Noes 0. Page 4134.) |
| May 4, 2026 | Read. Adopted. (Ayes 40. Noes 0.) |
| Apr 29, 2026 | From committee: Ordered to third reading. |
| Apr 27, 2026 | Introduced. Referred to Com. on RLS. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 4, 2026 | Senate 3rd Reading SR103 Blakespear et al. | Senate Floor |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SR 103 |
THIRD READING
Bill No: SR 103
Author: Blakespear (D), et al.
Introduced: 4/27/26
Vote: Majority
SUBJECT: Tardive Dyskinesia Awareness Week
SOURCE: Author
DIGEST:
This resolution proclaims the first full week in May 2026 as “Tardive Dyskinesia Awareness Week” (TDAW), and, in recognition and support of TDAW, underscores the importance of early detection and intervention to improve outcomes for people living with mental health conditions and prescribed antipsychotics and supports efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening.
ANALYSIS: This resolution makes the following legislative findings:
- Serious mental illnesses like bipolar disorder, major depressive disorder, and schizophrenia often require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates continue to rise.
- While prolonged antipsychotic use may be essential for the treatment of certain conditions, it is associated with tardive dyskinesia (TD), a condition marked by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, or extremities.
- Approximately 60% of the estimated 800,000 adults in the United States living with TD remain undiagnosed, and even mild TD symptoms can be stigmatizing and impair physical, social, and emotional well-being, underscoring the urgency of early screening, detection, and intervention.
- California can encourage TD screening education and awareness for health care providers, patients, and care partners to help ensure patients prescribed antipsychotics receive care and support that aligns with clinical best practices, including regular TD screenings.
This resolution proclaims the first full week in May 2026 as “Tardive Dyskinesia Awareness Week” (TDAW), and, in recognition and support of TDAW, underscores the importance of early detection and intervention to improve outcomes for people living with mental health conditions and prescribed antipsychotics and supports efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening.
Related/Prior Legislation
SCR 68 (Blakespear, Resolution Chapter 124, Statutes of 2025)
SR 87 (Blakespear, 2024) – Adopted in Senate.
HR 19 (Boerner, 2023) – Adopted in Assembly.
SR 30 (Archuleta, 2023) – Adopted in Senate.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
SUPPORT: (Verified 4/29/26)
None received
OPPOSITION: (Verified 4/29/26)
None received
Prepared by: Hunter Flynn / SFA / (916) 651-4171
4/29/26 16:22:21
**** END ****
Bill Author
Bill Co-Author(s):